Back Menu
id опорной категории = 5
id текущей категории = 20
id родительской категории = 5For Investors

Financial Highlights

International Financial Reporting Standards (IFRS):

6mo 2020 consolidated results (reviewed)

‘000 RUB 6mo 2020 6mo 2019 (as restated)* % change, y-o-y
Revenue from products and services:
Genetico® center & lab (genetic testing and counselling) 141,534 184,057 -23.10%
Gemabank® (isolation. cryоpreservation and personal storage of cord blood & umbilical cord stеm cells) 124,262 120,146 3.43%
Reprobank® (reproductive cell and tissue bank: donation, personal storage, transfer) 36,898 34,913 5.69%
Neovasculgen® 62,978 8,075 by a factor of 7.8
SPRS-therapy® 15,299 23,968 -36.17%
Royalties 10,000 13,432 -25.55%
Sale of antibody tests for COVID-19 43,254 n/a
Antibody testing for COVID-19 services 18,802 n/a
R&D agreements 126 125 0.80%
Other revenue 240 n/a
Total revenue 453,153 384,956 17.72%
Wages, salaries, other benefits and payroll taxes (136,428) (121,955) 11.87%
Rental fee (7,940) (8,873) -10.52%
Supplies and reagents (55,129) (68,081) -19.02%
Services of third-party organizations (contractors) (24,693) (10,230) 141.38%
Consulting and legal services (13,200) (10,201) 29.40%
Advertising costs (20,706) (13,150) 57.46%
R&D costs (1,671) n/a
Transportation and Travel expenses (11,403) (13,304) -14.29%
Bad debt recovery/ (expense) (32,603) (20,187) 61.50%
Telecommunications services. software and maintenance (4,778) (7,884) -39.40%
Audit fees (1,082) (1,011) 7.02%
Other operating expenses (5,483) (4,517) 21.39%
Operating expenses before depreciation & amortization (313,445) (281,064) 11.52%
OIBDA 139,708 103,892 34.47%
OIBDA margin, % 30.83% 26.99% n/a
Depreciation & amortization (35,160) (31,014) 13.37%
Total operating expenses (348,605) (312,078) 11.70%
Operating profit / (loss) 104,548 72,878 43.46%
Operating margin, % 23.07% 18.93% n/a
Other income/ (loss) – net, incl. (24,006) (8,984) 167.21%
Net interest expense (interest income + interest expense) (14,363) (19,813) -27.51%
Other non-operating income / (loss) — net (8,735) 9,780 n/a
Foreign exchange gain / (loss), net (908) 1,049 n/a
Profit / (loss) before income tax 80,542 63,894 26.06%
Income tax 11,730 (1,057) n/a
Profit/ (loss) for the period (net profit/ (loss)) 92,272 62 ,837* 46.84%
Net margin, % 20.36% 16.32% n/a
Other comprehensive income, net of tax n/a
Total comprehensive income / (loss) for the period, net of tax 92,272 62 ,837* 46.84%

*For details, see Note 4.3 to HSCI’s condensed consolidated interim financial statements as of and for the 6-month period ended June 30, 2020 under IFRS
Press-release on 6mo 2020 IFRS results

 

Сonsolidated Revenue Dynamics & Breakdown (under IFRS)

HSCI’s Сonsolidated Revenue (for the last 5 years, RUB thousands)

 

 

Consolidated Revenue Breakdown